Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.

Shuguang JuChen ZhouJunwen HuYingliang WangChaoyang WangJiacheng LiuChongtu YangSongjiang HuangTongqiang LiYang ChenYaowei BaiWei YaoBin Xiong

Published in: BMC cancer (2022)

TACE combined with apatinib plus camrelizumab for patients with unresectable HCC has promising antitumor activity and a manageable safety profile. For unresectable HCC with large tumor burden, late combination provides better OS and PFS compared to early combination.

Keyphrases

liver metastases
locally advanced
radiofrequency ablation
risk factors
radiation therapy